October 26 Earnings: Gilead - Flying the KiteGilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform. The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA. Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance. Generic competition will continue to weigh, however, and limit some blockbuster drug expansion. I'm starting Gilead with a $90 PT for an extended post-earnings move. A S/L at $75 around recent area is advised. Longby TraderDanERPublished 5
I love GILD chart!!I been watching this stock for a while now . It has earnings next month. So, i expect some sideways movement till then but its a good set up. Let's take a look. Monthly: Macd is crossed up. Price is between Tenkan and Kijun . Weekly: Macd is crossed up. Price is at resistance bit above Tenkan and Kijun. LT trendline has been broken. Chikou is above price. Daily: Bullish ichimoku. But macd is crossed down and chikou is below price . So, I am looking for Breakout on weekly for me to go long. Patience is needed as of now. I want to see the earnings reaction before taking a position. I don't gamble. We'll see if it proves itself bullish again. Otherwise, it's a no go. Thought to share Thanks guysLongby xChampi0nxPublished 3
GILD new up rise wave.GILD is about to begin new upward trend takes prices to new high. Watch it for by Nawaf__Q8Published 112
GILD ... buy/add on the dipthe coo retiring is not the reason for the drop... it may have to a firm taking profits... or the reopening of the false claim act for sales a decade ago... maximum penalty will like be 500-700 million...technicals intactLongby mazdakiPublished 0
Gilead holds .382 of recent advanceDecent close on weak day. Held .5 retrace intraday and .382 on closeLongby jayvoimiaPublished 1
feels like mid-Julypulled back after new highs, supported by 20 day. Will swing calls on strength Tuesday.Longby JackyChartsPublished 2
Took profits FridayReduced overall book risk. Will reenter low 80s / high 70s on pullback. by JackyChartsPublished 2
LONG GILDWait for confirm break of strong resistance at 85.22 (entry point). Rupture of negative tendency and newly formed tendency upwards. Could be the star of a beautiful run for GileadLongby javierarribasPublished 2
GILD dojiGILD made a doji today and a green candle tomorrow could spell continuation to the upside.by wave3tradingPublished 6
9.1.17 | Stock Picks || ATW | HIMX | RGC | KR | BZUN | YNDX | INTC | LULU | MSFT | ABBV | XOM | WMT | GILD | ADI | V | PANW | (Code-Name_Virtue) Here is my Stock Picks list, I will not be providing any analysis for any of these symbols because there are so many. I may however provide analysis for one or two of the symbols next week. Otherwise please use your own methods of analysis when considering any of the companies on my Stock Picks list. If you scroll down you will see I have a chart posted for each symbol in my updates therefore you can get a glance at any of the stocks that you may be interested in or have a Trade Idea for. (Keymaker) Thank You.by TrilogyAnalysisUpdated 334
Breakout and Waiting for a retest to buyBreakout Down Trend, Elliott Wave, Supply and DemandLongby TieuLongFXPublished 3
Gilead Biotech Aiming HighAlthough the ideas I share with you all revolve around currency pairs, I thought I'd share another specialty of mine: Biotech and pharma stock. If you're in the field, you may have already heard about Gilead having one of the best price to earning ratio of the major biotech companies. You may have also noticed the sharp decline that they experienced in the summer of 2015 which has largely been attributed to a loss in momentum due to the expiration of their patents and increased competition in the market. One could also argue that investors selling their stock contributed to the snowballing drop that seems to still be underway. Despite all this, there has been a lot of positive news recently with current projects that were once in the pipeline (such as Harvoni and Sovaldi) that have now been approved for the treatment of Hepatitis C. This puts them squarely back in competition with AbbVie and other similarly sized companies. In addition to other projects, the temptation of selling put options on Gilead at this very attractive price should yield dividends within the coming years. That said, the reversal is still not quite there yet but this is a very long term play that you should be ready for. As with currency pairs, this idea can turn on a dime so you should always take the necessary precautions!Longby Cohiba93Updated 6